Why the study?
What are the characteristics and risk factors of high renal threshold for glucose excretion in patients with type 2 diabetes mellitus?
What are the characteristics and risk factors of high renal threshold for glucose excretion in patients with type 2 diabetes mellitus?
Answers are grounded in this paper and cite their sources.
The renal threshold for glucose excretion is elevated in patients with type 2 diabetes, particularly those who are older, have a longer duration of diabetes, and higher BMI, which may influence their response to SGLT-2 inhibitors.
Sodium glucose co-transporter 2 (SGLT-2) inhibitors are newly developed but promising medicine for type 2 diabetes. However, patients with a different renal threshold for glucose excretion (RT(G)) may have a different reaction to this medicine. Therefore, the objective of this study was to investigate the characteristics of RT(G) and its impact factors in patients with type 2 diabetes mellitus (T2DM). The clinical and laboratory data of 36 healthy individuals and 168 in-hospital patients with T2DM were collected and analyzed, RT(G) was calculated using blood glucose (BG) measured by dynamic BG monitoring, urinary glucose excretion (UGE) and estimated glomerular filtration rate (eGFR). The characteristics of RT(G) were investigated. The risk factors for high RT(G) were analyzed using non-conditional logistic regression analysis. Our results found that RT(G) of the T2DM group was higher than that of the healthy individuals (P < 0.05); and 22.22% from the healthy individuals group but 58.33% from the T2DM group had high RT(G). Age, duration of diabetes, body mass index (BMI), and homeostasis model assessment insulin resistance index (HOMA-IR) were independently associated with high RT(G) (P < 0.05). Further stratified analysis revealed that RT(G) in T2DM patients increased with age, duration of diabetes, and BMI. In conclusion, RT(G) is increased in patients with T2DM, especially in those with longer diabetic duration, higher BMI, and those who are older. Therefore, these patients may be more sensitive to SGLT-2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: